Correa TL, Duong N. Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes. World J Hepatol 2025; 17(11): 112573 [DOI: 10.4254/wjh.v17.i11.112573]
Corresponding Author of This Article
Tulio L Correa, MD, Division of General Internal Medicine, University of Pittsburgh Medical Center, No. 200 Lothrop Street, Pittsburgh, PA 15213, United States. correatl@upmc.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nov 27, 2025 (publication date) through Dec 4, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Correa TL, Duong N. Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes. World J Hepatol 2025; 17(11): 112573 [DOI: 10.4254/wjh.v17.i11.112573]
World J Hepatol. Nov 27, 2025; 17(11): 112573 Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.112573
Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes
Tulio L Correa, Nikki Duong
Tulio L Correa, Division of General Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, United States
Nikki Duong, Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA 94608, United States
Author contributions: Correa TL contributed to the conceptualization and design of the review, drafted the original manuscript, and prepared the figures; Correa TL and Duong N performed data and evidence acquisition and interpretation; Duong N critically reviewed the manuscript, providing substantial intellectual input. Both authors approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tulio L Correa, MD, Division of General Internal Medicine, University of Pittsburgh Medical Center, No. 200 Lothrop Street, Pittsburgh, PA 15213, United States. correatl@upmc.edu
Received: July 31, 2025 Revised: August 26, 2025 Accepted: November 6, 2025 Published online: November 27, 2025 Processing time: 119 Days and 14.1 Hours
Core Tip
Core Tip: The transition from non-alcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease refocuses diagnosis on metabolic dysfunction, capturing a broader spectrum of patients with type 2 diabetes mellitus and hepatic steatosis. Metabolic dysfunction-associated steatotic liver disease and its related category, metabolic and alcohol-associated liver disease, improve disease recognition, prevalence estimation, and management strategies compared to non-alcoholic fatty liver disease. This minireview highlights the clinical implications of these changes, including the need for reclassification in trials, metabolic-targeted treatments, and multidisciplinary approaches to enhance screening and outcomes in type 2 diabetes mellitus populations.
